You are here

  • Home
  • Archive
  • Volume 7, Issue 3
  • Adjustment of antihypertensive medication using home based, patient monitored blood pressure reduced both intensity of treatment and blood pressure control

Article Text

Article menu
Download PDFPDF
Treatment
Adjustment of antihypertensive medication using home based, patient monitored blood pressure reduced both intensity of treatment and blood pressure control

https://doi.org/10.1136/ebn.7.3.80

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Staessen JA, Den Hond E, Celis H, et al for the Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators. Antihypertensive treatment based on blood pressure measurement at home or in the physician’s office: a randomized controlled trial. JAMA 2004;291:955–64.OpenUrlCrossRefPubMedWeb of Science

    Q Is home based, self measurement of blood pressure (BP) more effective than office based, physician measurement as a basis for initiating and titrating antihypertensive drug treatment?

    METHODS

    Embedded ImageDesign:

    randomised controlled trial.

    Embedded ImageAllocation:

    concealed.

    Embedded ImageBlinding:

    blinded {patients, physician making treatment decisions, outcome assessors, data analysts, and monitoring committee}*.

    Embedded ImageFollow up period:

    1 year.

    Embedded ImageSetting:

    56 primary care practices and 3 hospital based outpatient clinics in Leuven, Belgium and a specialised hypertension clinic in Dublin, Ireland.

    Embedded ImagePatients:

    400 patients ⩾18 years of age (mean age 53 y, 52% women) who had either untreated or treated hypertension (using ⩽2 antihypertensive agents), and the last of 3 consecutive readings …

    View Full Text

    Footnotes

    • ↵* Information provided by author.

    • For correspondence: Dr J A Staessen, University of Leuven, Leuven, Belgium. jan.staessenmed.kuleuven.ac.be

    • Sources of funding: AstraZeneca NV (Brussels) and AstraZeneca Pharaceuticals Ltd (Dublin). Pfizer NV (Brussels) donated amlodipine and prazosin.